Avrobio Inc. and Magenta Therapeutics have formed a research and clinical collaboration agreement to evaluate the potential utility of MGTA-117, Magenta’s novel targeted antibody-drug conjugate (ADC) for conditioning patients before they receive one of Avrobio’s investigational lentiviral gene therapies.   The collaboration will combine Avrobio’s leadership in lentiviral gene therapies with Magenta’s expertise in ADC-based conditioning. Under the collaboration, Avrobio and Magenta will jointly e...